Oral News and Research

RSS

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Dental health affects control of diabetes

Diabetes is a disease that affects every part of the body, and for people with unstable blood glucose levels there is a higher risk than normal for developing serious complications from poor oral hygiene. In a study by dLife, the world's largest diabetes community, and SoundView Research, Inc., 66 percent of active diabetes managers had not changed their oral care habits since being diagnosed and over half have not been advised by their dentist to take extra care to brush, floss, or rinse daily.

29 Oct 2010

GSK and Amicus announce Amigal development and commercialization agreement

GlaxoSmithKline PLC (GSK) and Amicus Therapeutics today announced a definitive agreement to develop and commercialize Amigal™ (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease, a rare inherited disorder. Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl.

29 Oct 2010

Eating disorders negatively affect oral health

While the connection between oral health and systemic health has been well-established, what most people don't know is that dentists often are in a position to detect systemic conditions. According to an article published in the October 2010 issue of AGD Impact, the monthly newsmagazine of the Academy of General Dentistry (AGD), dentists may be the first health care providers to notice evidence of an eating disorder, such as anorexia nervosa, bulimia nervosa, binge eating disorder, and pica.

29 Oct 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

VIVUS receives FDA CRL for QNEXA NDA

VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

29 Oct 2010

Study finds site of tumor impacts disease stage in head and neck cancer

Developing a molecular fingerprint for head and neck cancer tumors could help improve diagnosis and treatment for this deadly and often-times disfiguring form of cancer, according to researchers at Henry Ford Hospital in Detroit.

29 Oct 2010

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

The first national outcome-based contract between a pharmaceutical company and a pharmacy benefit management company resulted in an increase in the number of people with type 2 diabetes who were able to control their blood sugar levels by taking their medications appropriately.

29 Oct 2010

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter and nine months ended September 30, 2010.

28 Oct 2010

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

QLT Inc. today announced expansion of the Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber Congenital Amaurosis (LCA) to include patients with Retinitis Pigmentosa (RP), a set of hereditary retinal diseases demonstrating clinical features similar to LCA.

28 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

GEB device effective for nasotracheal intubation

An alternative anesthetic technique can be employed when conventional nasal intubation methods do not work.. The method involves a gum elastic bougie (GEB) device, which is useful for difficult airway management but seldom has been used for nasotracheal intubation.

28 Oct 2010

Causes, prevention, and management of inferior alveolar nerve injury during implant dentistry

Although implant dentistry has become widely accepted to restore esthetics and function of teeth, it is not without risks. One serious complication that can occur is alteration of sensation due to nerve injury. Some reports place this occurrence as high as 13%. For dental practitioners, thorough understanding of anatomy, surgical procedures, and implant systems along with proper planning of treatment are essential to reduce this complication.

28 Oct 2010

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period.

28 Oct 2010

Polio vaccination campaign targeting 72M children in 15 African countries announced; Ugandan health authorities declare polio outbreak

The WHO on Tuesday announced a mass polio immunization campaign in 15 African countries targeting a total of 72 million children, Agence France-Presse reports. "Polio has spread again in recent years with cases imported from some of the four endemic nations in Asia and Africa, mainly Nigeria, in a setback to global attempts to eradicate the crippling and sometimes lethal disease," the news service writes (10/26).

28 Oct 2010

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).

28 Oct 2010

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

Oral News and Research

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

Dental health affects control of diabetes

GSK and Amicus announce Amigal development and commercialization agreement

Eating disorders negatively affect oral health

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

VIVUS receives FDA CRL for QNEXA NDA

Study finds site of tumor impacts disease stage in head and neck cancer

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

GEB device effective for nasotracheal intubation

Causes, prevention, and management of inferior alveolar nerve injury during implant dentistry

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

Polio vaccination campaign targeting 72M children in 15 African countries announced; Ugandan health authorities declare polio outbreak

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News